US2004162269A1PendingUtilityA1

Composition and method of treating arthritis

Priority: Sep 9, 1998Filed: Feb 5, 2002Published: Aug 19, 2004
Est. expirySep 9, 2018(expired)· nominal 20-yr term from priority
A61K 45/06A61K 31/7004
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to the composition and method of treating arthritis, repairing of articular joint surfaces and the relief of symptoms associated with arthritis. The composition comprises a nitric oxide synthase inhibitor and amino sugars. The nitric oxide synthase inhibitor reduces the level of nitric oxide, the free radical believed responsible for the degradation of articular cartilage. Amino sugars are the building blocks of articular cartilage and have anti-inflammatory actions.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treating arthritis in mammals by administering a therapeutically effective amount of a composition comprising: 
 a) an inhibitor of nitric oxide synthase, and    b) an aminosugar.    
     
     
         2 . The method of  claim 1 , wherein said aminosugar in the composition is selected from the group consisting of: glucosamine, glucosamine hydrochloride, glucosamine sulfate, N-acetylglucosamine and mixtures thereof.  
     
     
         3 . The method of  claim 1 , wherein the composition optionally contains additional agents selected from the group consisting of: glycosaminoglycans, vitamin A, vitamin B, vitamin E, selenium, silica, manganese, magnesium, copper, boron, analgesics, anti-inflammatory agents, methyl-sulfonyl-methane, S-adenosyl-methionine, alpha-lipoic acid, aloe vera extract, antioxidants, anti-infective agents, adjuvants, anthocyanidins, proanthocyanidins, and herbal derivatives, and mixtures thereof.  
     
     
         4 . The method of  claim 1 , wherein said composition has an enteric coating to deliver the composition orally in a controlled release into the gastrointestinal tract.  
     
     
         5 . The method of  claim 1 , wherein the composition further comprises a carrier suitable for oral, rectal, parental, intravenous, topical, transdermal, subcutaneous, and intramuscular administration.  
     
     
         6 . The method of  claim 1 , wherein said inhibitors of nitric oxide synthase include zinc compounds, arginine derivatives, flavoprotein binders, diphenylene iodonium and derivatives thereof, ornithine and derivatives thereof, N-imino-ethyl-L-ornithine, tetracycline, L-canavanine, citrulline, redox dyes, methylene blue, calmodulin binders, trifluoropiperazine, calcinarin, heme binders, tetrahydropterin derivatives, aminoguanidine, depleters of biopterin, methotrexate, nonsteroidal anti-inflammatory agents, sodium salicylate, and mixtures thereof.  
     
     
         7 . The method of  claim 6 , wherein said arginine derivitives include methylated arginines, substituted L-arginine, nitro-arginine, L-N G -nitroarginine, N G -monomethyl-L-arginine (NMA), N-nitro-L-arginine methyl ester, N-amino-L-arginine, N-methyl-L-arginine, N G -monomethyl-L-arginine (L-NMA), L-N G -monomethylarginine (L-NMMA).

Join the waitlist — get patent alerts

Track US2004162269A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.